CJC-1295 WITH AND WITHOUT DAC: AN EVIDENCE-BASED RESEARCH REVIEW
Research status: Experimental research compounds
Evidence base: Preclinical and limited human research
Human evidence: Published human pharmacology research exists for long-acting CJC-1295 with DAC
CJC-1295 without DAC: Evidence should be considered separately
Regulatory status: Not an approved medicine for general therapeutic use
INTRODUCTION
CJC-1295 is a synthetic peptide analogue associated with research into growth hormone-releasing hormone signalling.
The term CJC-1295 is commonly encountered in two different contexts: CJC-1295 with Drug Affinity Complex, known as DAC, and material commonly described as CJC-1295 without DAC.
This distinction is important when interpreting the scientific literature.
The original CJC-1295 investigated in published human research incorporated a chemical modification designed to facilitate binding to circulating albumin. This substantially extended its biological persistence.
Material described as CJC-1295 without DAC does not possess the same albumin-binding characteristic and should not automatically be considered pharmacologically equivalent to the long-acting compound.
Consequently, evidence generated using CJC-1295 with DAC should not automatically be attributed to CJC-1295 without DAC.
This article examines the research surrounding these materials, their relationship with growth hormone-releasing hormone signalling, available human evidence and important limitations within the current literature.
WHAT IS CJC-1295?
CJC-1295 was developed as an analogue of growth hormone-releasing factor.
Growth hormone-releasing hormone is involved in the physiological regulation of growth hormone secretion from the anterior pituitary.
Researchers have investigated modified analogues to understand how structural changes can influence stability, receptor activity and pharmacokinetic behaviour.
The compound originally described as CJC-1295 incorporated structural modifications intended to increase stability together with a Drug Affinity Complex designed to facilitate binding to serum albumin.
This albumin association substantially alters the pharmacokinetic characteristics of the peptide.
For this reason, the presence or absence of DAC is scientifically significant.
WHAT DOES DAC MEAN?
DAC stands for Drug Affinity Complex.
This technology was developed to extend the circulating persistence of certain peptide compounds through association with serum albumin.
Albumin is a naturally occurring protein with a comparatively long residence time in circulation.
Research involving the original CJC-1295 demonstrated that its albumin-binding characteristics produced a prolonged pharmacokinetic profile compared with shorter-acting growth hormone-releasing hormone related peptides.
This property became one of the defining characteristics of the original CJC-1295 research programme.
CJC-1295 WITH DAC
CJC-1295 with DAC is the long-acting form most directly associated with the original published CJC-1295 research.
Preclinical research examined its interaction with albumin, stability, receptor activity and effects on endocrine signalling.
The compound subsequently progressed into controlled human pharmacology studies.
These studies provide direct evidence concerning the pharmacokinetic and pharmacodynamic characteristics of the long-acting compound.
However, evidence of endocrine activity does not establish therapeutic effectiveness.
CJC-1295 WITHOUT DAC
The terminology surrounding CJC-1295 without DAC requires additional care.
The name is commonly used for shorter-acting modified growth hormone-releasing hormone related peptides that do not contain the Drug Affinity Complex responsible for the prolonged albumin association of original CJC-1295.
Accordingly, CJC-1295 with DAC and material described as CJC-1295 without DAC should not be treated as identical research materials.
Removing the albumin-binding component changes an important pharmacological characteristic.
Research findings concerning the prolonged pharmacokinetics of CJC-1295 with DAC therefore cannot automatically be applied to material without DAC.
Precise compound identity is important when reviewing individual studies.
GROWTH HORMONE-RELEASING HORMONE RECEPTOR RESEARCH
Growth hormone-releasing hormone acts through receptors expressed on pituitary cells involved in growth hormone secretion.
Activation of these receptors participates in signalling associated with growth hormone synthesis and release.
Experimental research involving CJC-1295 and related analogues has investigated this pathway to understand how structural modifications affect receptor activity and biological persistence.
These studies provide information about molecular and endocrine mechanisms.
However, demonstrating receptor activity does not establish a clinical benefit.
PRECLINICAL RESEARCH
Before human investigation, CJC-1295 was examined in laboratory and animal models.
Research has investigated areas including:
Growth hormone-releasing hormone receptor activity
Peptide stability
Albumin association
Pharmacokinetics
Growth hormone responses
IGF-1 responses
Endocrine signalling
These studies contributed to the pharmacological characterisation of CJC-1295 and helped establish the importance of its albumin-binding properties.
As with other experimental compounds, preclinical findings cannot independently establish clinical effectiveness or long-term human safety.
HUMAN RESEARCH ON CJC-1295 WITH DAC
Published human research has investigated long-acting CJC-1295.
A 2006 study examined the pharmacokinetic and pharmacodynamic characteristics of CJC-1295 in healthy adults.
The research used randomised, placebo-controlled, double-blind dose-escalation study designs.
Researchers observed sustained changes in circulating growth hormone and IGF-1 following experimental administration.
The study also demonstrated prolonged pharmacokinetic characteristics associated with CJC-1295.
These findings provide evidence that long-acting CJC-1295 has measurable pharmacological activity in humans.
However, the research primarily evaluated pharmacokinetics and endocrine responses.
It did not establish CJC-1295 as a clinically proven treatment for broader proposed applications.
GROWTH HORMONE PULSATILITY RESEARCH
Additional human research examined growth hormone secretion following experimental exposure to long-acting CJC-1295.
Researchers investigated whether patterns of pulsatile growth hormone secretion remained observable during prolonged receptor stimulation.
This research contributed additional information about the endocrine pharmacology of CJC-1295.
These findings concern measurable biological responses rather than demonstrated therapeutic outcomes.
GROWTH HORMONE AND IGF-1 AS RESEARCH MARKERS
Growth hormone and IGF-1 are frequently measured in endocrine research.
Changes in these biomarkers can demonstrate that an experimental compound has pharmacodynamic activity.
However, a change in growth hormone or IGF-1 should not automatically be interpreted as evidence of a wider physiological or clinical benefit.
Biomarker responses and clinical outcomes represent different levels of evidence.
Claims concerning specific outcomes require research designed specifically to measure those outcomes.
EVIDENCE FOR CJC-1295 WITHOUT DAC
Evidence concerning material described as CJC-1295 without DAC should be interpreted separately.
The absence of the Drug Affinity Complex means that the pharmacokinetic properties demonstrated for long-acting CJC-1295 cannot simply be transferred to material without DAC.
There is also substantially less direct clinical evidence specifically characterising material marketed under the CJC-1295 without DAC terminology.
Research involving growth hormone-releasing hormone fragments and related modified analogues provides relevant scientific background concerning shorter-acting compounds.
However, related research should not be represented as direct evidence for every material commercially described as CJC-1295 without DAC.
WHY COMPOUND IDENTITY MATTERS
Small structural differences can materially alter peptide pharmacology.
Relevant characteristics include:
Amino acid sequence
Chemical modifications
Albumin-binding properties
Peptide stability
Receptor activity
Pharmacokinetics
Manufacturing characteristics
For this reason, evidence generated using one peptide formulation should not automatically be attributed to another.
This is particularly important when distinguishing CJC-1295 with DAC from material described as CJC-1295 without DAC.
BIOLOGICAL ACTIVITY VERSUS CLINICAL EFFECTIVENESS
Experimental research may demonstrate changes in receptor activity, growth hormone concentrations, IGF-1 concentrations, endocrine signalling and pharmacokinetic characteristics.
These findings provide information about biological and pharmacological activity.
They do not independently establish clinical effectiveness.
They also do not independently establish effects on body composition, physical performance, recovery, ageing, sleep or general health.
Evidence of biological activity should therefore be distinguished from evidence of a clinically meaningful outcome.
Each proposed outcome requires appropriate research designed specifically to investigate that question.
UNDERSTANDING THE EVIDENCE HIERARCHY
LABORATORY RESEARCH
Laboratory studies can investigate receptor interactions, molecular stability and biological mechanisms.
These findings cannot establish clinical effectiveness.
ANIMAL RESEARCH
Animal models allow pharmacological activity to be examined within living biological systems.
Animal findings cannot automatically be extrapolated to humans.
HUMAN PHARMACOLOGY RESEARCH
Human pharmacokinetic and pharmacodynamic studies can establish whether a compound produces measurable biological responses and provide information about its behaviour under controlled research conditions.
These studies do not necessarily establish therapeutic effectiveness.
CONTROLLED CLINICAL OUTCOME RESEARCH
Establishing a clinical application requires appropriately designed studies evaluating the relevant clinical outcomes.
Changes in biological markers alone are insufficient to establish therapeutic effectiveness.
CURRENT RESEARCH LIMITATIONS
DIFFERENT COMPOUND CATEGORIES
CJC-1295 with DAC and material described as CJC-1295 without DAC have important pharmacological differences and should not be treated as interchangeable.
UNEQUAL HUMAN EVIDENCE
The strongest direct human evidence concerns the long-acting DAC-containing form of CJC-1295.
LIMITED OUTCOME RESEARCH
Much of the published human research focuses on pharmacokinetics and endocrine biomarkers rather than established clinical outcomes.
BIOLOGICAL MARKERS
Changes in growth hormone and IGF-1 represent biological responses and do not independently establish therapeutic benefit.
LONG-TERM EVIDENCE
Comprehensive long-term human safety information has not been established.
TRANSLATIONAL UNCERTAINTY
Findings from laboratory and animal studies cannot automatically be extrapolated to human outcomes.
CURRENT RESEARCH ASSESSMENT
CJC-1295 is best understood as an experimental growth hormone-releasing hormone analogue investigated for its effects on endocrine signalling and growth hormone physiology.
The original long-acting CJC-1295 with DAC has published preclinical and human pharmacology research demonstrating prolonged pharmacokinetic characteristics and measurable effects on growth hormone and IGF-1.
Material commonly described as CJC-1295 without DAC represents a different research category because it lacks the albumin-binding characteristic central to the original long-acting compound.
Evidence concerning the two forms should therefore be evaluated separately.
Neither pharmacological activity nor changes in endocrine biomarkers establish therapeutic effectiveness.
EVIDENCE SUMMARY
CJC-1295 with DAC laboratory research: Published evidence
CJC-1295 with DAC animal research: Published evidence
CJC-1295 with DAC human pharmacology: Published evidence
CJC-1295 with DAC endocrine response: Published evidence
CJC-1295 without DAC direct human evidence: Limited and less clearly characterised
Clinical outcome evidence: Limited
Long-term human safety: Not established
Established therapeutic indication: None
CONCLUSION
CJC-1295 represents an area of experimental growth hormone-releasing hormone analogue research.
The original CJC-1295 with DAC was developed to produce prolonged biological persistence through albumin association.
Preclinical and controlled human studies have characterised aspects of its pharmacokinetics and endocrine activity.
Material commonly described as CJC-1295 without DAC lacks this defining albumin-binding component and should not automatically be treated as equivalent to the compound investigated in the principal CJC-1295 human studies.
For researchers, distinguishing between these materials is essential when interpreting published evidence.
Current evidence demonstrates pharmacological activity for long-acting CJC-1295 but does not establish broader therapeutic effectiveness.
Further appropriately designed research would be required to determine the clinical significance and long-term safety of these experimental compounds.
RESEARCH CONTEXT
Discussion of published human research is included solely to provide an accurate summary of the scientific literature.
The existence of human studies involving CJC-1295 does not imply that products supplied by Evolve Peptides are intended, approved or supplied for human use.
Research concerning CJC-1295 with DAC should not automatically be attributed to material described as CJC-1295 without DAC.
REFERENCES
Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor 1-29 albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PMID 15817669.
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006. PMID 16352683.
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006. PMID 17018654.
Sackmann-Sala L, et al. Activation of the GH and IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone and IGF Research. 2009. PMID 19386527.
Ling N, Baird A, Wehrenberg WB, Ueno N, Munegumi T, Brazeau P. Synthesis and in vitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor. Biochemical and Biophysical Research Communications. 1984. PMID 6435620.
RESEARCH DISCLAIMER
This article is provided for educational and scientific research purposes only.
CJC-1295 with DAC and material described as CJC-1295 without DAC are experimental research compounds and should not be represented as approved medicines or clinically proven treatments.
Evidence demonstrating receptor activity, endocrine responses, pharmacokinetic characteristics or other experimental biological effects does not establish clinical efficacy or long-term safety.
Research involving one CJC-1295 form should not automatically be attributed to another.
Research findings should always be interpreted according to compound identity, study design, experimental model, methodology and the level of evidence available.
Products supplied by Evolve Peptides are intended strictly for laboratory and scientific research purposes and are not intended for human or veterinary use.
